Advanced Tools for Cancer Biomarker Discovery and Validation

As a gene-centric company, OriGene has developed new technologies and products for cancer biomarker discovery and validation

Tissue Biorepository

  • More than 140,000 tissues from U.S. Hospitals
  • Collected under strict IRB practices
  • Annotated with clinical data

TissueScan

  • mRNA expression profiling via qPCRs
  • Panels of normalized cDNA prepared from tumor tissues
  • Including breast, colon, lung, ovarian and prostate

qPCR primer Panels

  • 21 pre-designed key cancer pathways
  • qPCR screening-ready formats
  • Custom panels available

Cancer Research Targets